244 related articles for article (PubMed ID: 26134233)
21. An update of ALK inhibitors in human clinical trials.
Chan EL; Chin CH; Lui VW
Future Oncol; 2016 Jan; 12(1):71-81. PubMed ID: 26618223
[TBL] [Abstract][Full Text] [Related]
22. Ceritinib versus chemotherapy in ALK-positive lung cancer.
Marshall H
Lancet Respir Med; 2016 Dec; 4(12):952-953. PubMed ID: 27838332
[No Abstract] [Full Text] [Related]
23. Successful treatment with ceritinib after crizotinib induced hepatitis.
Sassier M; Mennecier B; Gschwend A; Rein M; Coquerel A; Humbert X; Alexandre J; Fedrizzi S; Gervais R
Lung Cancer; 2016 May; 95():15-6. PubMed ID: 27040846
[TBL] [Abstract][Full Text] [Related]
24. [Result of Clinical Trials of Ceritinib in Patients with ALK-Rearranged Non-Small-Cell Lung Cancer and Management of the Adverse Events].
Satouchi M; Nishio M; Hida T; Nakagawa K
Gan To Kagaku Ryoho; 2018 Feb; 45(2):257-264. PubMed ID: 29483416
[TBL] [Abstract][Full Text] [Related]
25. Ceritinib in ALK-rearranged non-small-cell lung cancer.
Shen L; Ji HF
N Engl J Med; 2014 Jun; 370(26):2537. PubMed ID: 24963576
[No Abstract] [Full Text] [Related]
26. Ceritinib in ALK-rearranged non-small-cell lung cancer.
Shaw AT; Engelman JA
N Engl J Med; 2014 Jun; 370(26):2537-9. PubMed ID: 24963575
[No Abstract] [Full Text] [Related]
27. Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?
Rolfo C; Passiglia F; Russo A; Pauwels P
Expert Opin Ther Targets; 2014 Sep; 18(9):983-5. PubMed ID: 24998601
[TBL] [Abstract][Full Text] [Related]
28. Ceritinib for the treatment of non-small cell lung cancer.
Landi L; Cappuzzo F
Drugs Today (Barc); 2014 Jul; 50(7):465-73. PubMed ID: 25101329
[TBL] [Abstract][Full Text] [Related]
29. Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA.
Johnson AC; Dô P; Richard N; Dubos C; Michels JJ; Bonneau J; Gervais R
Lung Cancer; 2016 Sep; 99():38-40. PubMed ID: 27565911
[TBL] [Abstract][Full Text] [Related]
30. Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors.
Wang HY; Ho CC; Shih JY
J Thorac Oncol; 2017 May; 12(5):e49-e51. PubMed ID: 28434515
[No Abstract] [Full Text] [Related]
31. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
Toyokawa G; Seto T
Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic management of ALK+ nonsmall cell lung cancer patients.
Duchemann B; Friboulet L; Besse B
Eur Respir J; 2015 Jul; 46(1):230-42. PubMed ID: 25929953
[TBL] [Abstract][Full Text] [Related]
33. Ceritinib for the treatment of late-stage (metastatic) non-small cell lung cancer.
Massarelli E; Papadimitrakopoulou V
Clin Cancer Res; 2015 Feb; 21(4):670-4. PubMed ID: 25564153
[TBL] [Abstract][Full Text] [Related]
34. Ceritinib (Zykadia) for non-small cell lung cancer.
Med Lett Drugs Ther; 2014 Jul; 56(1447):62-3. PubMed ID: 25046419
[No Abstract] [Full Text] [Related]
35. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.
Dardaei L; Wang HQ; Singh M; Fordjour P; Shaw KX; Yoda S; Kerr G; Yu K; Liang J; Cao Y; Chen Y; Lawrence MS; Langenbucher A; Gainor JF; Friboulet L; Dagogo-Jack I; Myers DT; Labrot E; Ruddy D; Parks M; Lee D; DiCecca RH; Moody S; Hao H; Mohseni M; LaMarche M; Williams J; Hoffmaster K; Caponigro G; Shaw AT; Hata AN; Benes CH; Li F; Engelman JA
Nat Med; 2018 May; 24(4):512-517. PubMed ID: 29505033
[TBL] [Abstract][Full Text] [Related]
36. Patient-derived models of acquired resistance can identify effective drug combinations for cancer.
Crystal AS; Shaw AT; Sequist LV; Friboulet L; Niederst MJ; Lockerman EL; Frias RL; Gainor JF; Amzallag A; Greninger P; Lee D; Kalsy A; Gomez-Caraballo M; Elamine L; Howe E; Hur W; Lifshits E; Robinson HE; Katayama R; Faber AC; Awad MM; Ramaswamy S; Mino-Kenudson M; Iafrate AJ; Benes CH; Engelman JA
Science; 2014 Dec; 346(6216):1480-6. PubMed ID: 25394791
[TBL] [Abstract][Full Text] [Related]
37. Ceritinib: first global approval.
Dhillon S; Clark M
Drugs; 2014 Jul; 74(11):1285-91. PubMed ID: 24980964
[TBL] [Abstract][Full Text] [Related]
38. Crizotinib: an anaplastic lymphoma kinase inhibitor.
Gadgeel SM; Bepler G
Future Oncol; 2011 Aug; 7(8):947-53. PubMed ID: 21823889
[TBL] [Abstract][Full Text] [Related]
39. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.
Huang D; Kim DW; Kotsakis A; Deng S; Lira P; Ho SN; Lee NV; Vizcarra P; Cao JQ; Christensen JG; Kim TM; Sun JM; Ahn JS; Ahn MJ; Park K; Mao M
Genomics; 2013 Sep; 102(3):157-62. PubMed ID: 23434628
[TBL] [Abstract][Full Text] [Related]
40. Overcoming drug resistance in ALK-rearranged lung cancer.
Thomas RK
N Engl J Med; 2014 Mar; 370(13):1250-1. PubMed ID: 24670172
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
